surmount 3 tirzepatide being discontinued Tirzepatide after intensive lifestyle intervention in adults with overweight or obesity: the SURMOUNT-3 phase trial SURMOUNT 1 // Three-Year Obesty

Its digitalis-like component (periplocymarin from Periploca) could synergize with prescribed digoxin, potentially increasing inotropic effectcaution is advised to watch for digitalis toxicity signs if patients are on both

Insulin: Hypoglycemia is the main concern

The role of IGF-I on thymus development and function, hematopoiesis and immune system reconstitution is well documented[158161]

[23] Constipation that worsens with fiber supplementation may suggest slow transit constipation or a defecatory disorder

The doses of liraglutide or semaglutide are different depending on whether the patient has DT2, is overweight (BMI 27kg/m2) with comorbidities or has obesity (with or without DT2)

The landmark SUSTAIN clinical trial programme, which evaluated Ozempic in patients with type 2 diabetes, reported small improvements in certain cholesterol parameters alongside significant reductions in body weight and HbA1c levels